Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBay Capital Share News (BAY)

Share Price Information for Bay Capital (BAY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £5.95m
BAY Live PriceLast checked at - London Stock Exchange

Intraday Bay Capital Share Chart

London open: Slow progress for blue chips

Fri, 29th Oct 2010 08:42
London has made modest early gains despite a poor session in Asia and unconvincing display on Wall Street overnight.British Airways is lower even though it swung to a profit in the first half as the airline improved yields and cut costs. It made a pre-tax profit of £158m in the six months ended 30 September compared a loss of £292m a year ago. Revenue jumped 8% to £4.45bn due to improved yields.WPP was also upbeat. The ad giant upped like-for-like revenues by 4.1% in the first nine months of its current year as companies restarted advertising spending after the recession with traditional ad spending outstripping online. Total revenue rose by 6.3% to £6.69bn with third quarter sales up 12.2% to £2.3bn. Operating margins also improved over last year.Prudential and Aviva are the best performers alongside oil groups Cairn, BP and Royal Dutch Shell.AstraZeneca will receive a $100m upfront payment from Daiichi Sankyo after agreeing a deal for the co-promotion and supply of Nexium, a proton pump inhibitor, in Japan. The Anglo-Swedish drugs giant will co-promote the product, used to treat gastroesophageal reflux disease (GERD) and stomach ulcers, once it is approved for use in Japan, making and developing the product, while Daiichi Sankyo will deal with distribution. Fund manager F&C Asset Management halted the recent outflow of funds in the past three months, but cautioned business may be weaker to the end of the year. Assets under management rose to £108.2bn from £95.3bn at the end of June. "While we are making good progress in our institutional business..., institutional asset flows remain lumpy from quarter to quarter. After a strong third quarter we currently anticipate weaker headline institutional asset flows in the fourth quarter," FCAM said.Hikma Pharmaceuticals becomes the second largest injectables supplier in the US after agreeing to pay $112m (£70m) in cash for Baxter Healthcare's generic injectables business. Oil services group Hunting expects to exceed current full year market expectations after trading remained very strong between July and October.FTSE 100 - RisersPrudential (PRU) 640.00p +1.51%Aviva (AV.) 398.50p +1.48%Cairn Energy (CNE) 392.80p +1.45%Lloyds Banking Group (LLOY) 68.87p +1.43%BG Group (BG.) 1,207.50p +1.43%FTSE 100 - FallersSmith & Nephew (SN.) 552.50p -1.34%Rio Tinto (RIO) 4,054.00p -1.25%Xstrata (XTA) 1,237.50p -1.00%Schroders (Non-Voting) (SDRC) 1,264.00p -0.94%FTSE 250 - RisersHikma Pharmaceuticals (HIK) 770.50p +4.62%Kenmare Resources (KMR) 20.05p +4.16%Hunting (HTG) 626.00p +3.81%Afren (AFR) 128.10p +2.07%CPP Group (CPP) 255.00p +2.00%FTSE 250 - FallersPremier Foods (PFD) 17.61p -2.17%Morgan Crucible Co (MGCR) 231.10p -1.87%Savills (SVS) 319.60p -1.72%Euromoney Institutional Investor (ERM) 637.50p -1.62%Senior (SNR) 135.40p -1.53%

Related News

AstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2
7 hours ago

AstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2

(Alliance News) - AstraZeneca PLC on Monday said the European Commission has approved Enhertu as the first tumour-agnostic HER2-directed therapy and a...

LONDON BRIEFING: BT, Verizon merge international arms in joint venture
7 hours ago

LONDON BRIEFING: BT, Verizon merge international arms in joint venture

(Alliance News) - BT and Verizon form international joint venture, Foresight increases its dividend while Plus500 adds to its US prediction markets of...

AstraZeneca's Datroway and Enhertu candidates receive EU approval
8 hours ago

AstraZeneca's Datroway and Enhertu candidates receive EU approval

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first...

Bay Capital News

WINNERS & LOSERS: Seraphim Space surges; Silver Bullet plans to delist
9 Jun 2026

WINNERS & LOSERS: Seraphim Space surges; Silver Bullet plans to delist

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.

EARNINGS: Titon half-year loss widens; Seplat quarterly profit down
1 May 2026

EARNINGS: Titon half-year loss widens; Seplat quarterly profit down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News...

DIRECTOR DEALINGS: Plus500 COO buys shares; Supreme PLC chief sells
2 Dec 2025

DIRECTOR DEALINGS: Plus500 COO buys shares; Supreme PLC chief sells

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced in the past week and not sep...

EARNINGS: itim widens loss; Ceiba and Union Jack Oil swing to loss
29 Sep 2025

EARNINGS: itim widens loss; Ceiba and Union Jack Oil swing to loss

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News:

EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles
24 Apr 2024

EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...